Algernon Pharmaceuticals (XCNQ:AGN) EBIT per Share : C$-0.10 (TTM As of Nov. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals EBIT per Share?

Algernon Pharmaceuticals's EBIT per Share for the three months ended in Nov. 2024 was C$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2024 was C$-0.10.

During the past 3 years, the average EBIT per Share Growth Rate was 52.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 36.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Algernon Pharmaceuticals's EBIT per Share or its related term are showing as below:

XCNQ:AGN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -20.2 Med: 18.8 Max: 52
Current: 52

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Algernon Pharmaceuticals was 52.00% per year. The lowest was -20.20% per year. And the median was 18.80% per year.

XCNQ:AGN's 3-Year EBIT Growth Rate is ranked better than
94.36% of 1224 companies
in the Biotechnology industry
Industry Median: 2.9 vs XCNQ:AGN: 52.00

Algernon Pharmaceuticals's EBIT for the three months ended in Nov. 2024 was C$-0.38 Mil.

Algernon Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Algernon Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals EBIT per Share Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

EBIT per Share

Get a 7-Day Free Trial

-2.06

-1.08

-0.87

-0.35

-0.12

Algernon Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
EBIT per Share	Get a 7-Day Free Trial															-0.03	-0.05	-0.02	-0.02	-0.01

Algernon Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Algernon Pharmaceuticals's EBIT per Share for the fiscal year that ended in Aug. 2024 is calculated as

	EBIT per Share		(A: Aug. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.412	/	20.048
=	-0.12

Algernon Pharmaceuticals's EBIT per Share for the quarter that ended in Nov. 2024 is calculated as

	EBIT per Share		(Q: Nov. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.381	/	27.301
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.10

Algernon Pharmaceuticals (XCNQ:AGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Algernon Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Executives

Christopher Moreau	Director, Senior Officer
Christopher Scott Bryan	Senior Officer
James Kinley	Senior Officer
Harry J.f. Bloomfield	Director
Rajpaul Attariwala	Director
Mark Williams	Director
Howard Gutman	Director
Michael Sadhra	Senior Officer
Kulwant Malhi	10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines